We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR

By LabMedica International staff writers
Posted on 20 Mar 2025

Each year, 11 million people across the world die of sepsis out of which 1. More...

3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily, complicating the detection of resistant pathogens. There is a need for clinicians to get accurate identification and faster antibiotic susceptibility test (AST) results, thereby enabling timely and appropriate patient intervention. Now, an innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) can benefit clinical laboratories to help diagnose infectious diseases and combat AMR.

bioMérieux’s (Marcy l'Etoile, France) VITEK® COMPACT PRO combines the latest diagnostic technology with the globally acknowledged advantages of its predecessor: VITEK® 2 COMPACT. With an ergonomically advanced design and a simplified workflow, it further enhances the user experience and improves overall efficiency as the laboratory technician has to spend less time for sample loading and processing. It offers one of the most efficient workflows, fastest routine ID/AST results and microbiology expertise for accurate and confident diagnostics insights.

Ideally suited for small and medium-sized laboratories, VITEK® COMPACT PRO also enables laboratories transitioning from manual workflows to benefit from automation efficiencies. bioMérieux has now received U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. The commercial launch of VITEK® COMPACT PRO is initially planned in select countries, followed by a global launch starting in the second quarter of 2025.

"For decades, bioMérieux has been an industry leader in microbiology innovation. With the introduction of VITEK® COMPACT PRO, we are continuing this journey and delivering on the specialized needs of our customers – supporting laboratories with simplified, efficient workflows and the latest technology to optimize their experience," said Jennifer Zinn, Executive Vice President, Clinical Operations. “Through ongoing expansion of our VITEK® solutions portfolio, bioMérieux continues to strengthen our comprehensive AMR/AMS offer and reinforce our commitment to provide next-generation ID/AST systems to healthcare and laboratory professionals around the world.”

"As a leader in the fight against AMR, bioMérieux continuously innovates by developing and renewing its key diagnostic solutions," added Céline Roger-Dalbert, Executive Vice President, Research and Development. “VITEK® COMPACT PRO delivers fast, accurate and reproducible results comparable to VITEK® 2 and VITEK® 2 COMPACT systems. The ergonomic features, a new intuitive user interface, and an updated software with one of the most comprehensive knowledge database makes VITEK® COMPACT PRO highly appealing to both clinical and industrial laboratories.”


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
New
Hemoglobin Stool Test
CerTest FOB 50 + 200 One Step Combo Card Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.